Therapy with immune checkpoint inhibitors (ICIs) such as targeting programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) has been proven to be effective anti-tumor agents in HCC (2). Here, PDCD1 is linked to hepatocellular carcinoma.